Study reveals pivotal insights into the progression of Parkinson’s disease

Parkinson’s disease, the second most common type of progressive dementia after Alzheimer’s disease, affects nearly 1 million people in the U.S. and an estimated 10 million individuals worldwide.

CSL’s ‘big’ post-heart attack drug fails in Phase III trial

Share this article CSL’s AEGIS-II study for its MI drug CSL112 enrolled 18,200 participants across 850 sites worldwide. Image Credit: viewimage / Shutterstock. Australian CSL

February 12, 2024

King Charles Admitted; ADHD Drug Recalled; Minnesota Debates Doc-Assisted Suicide

Note that some links may require registration or subscription. King Charles III has been admitted to a hospital in London to undergo a procedure for

January 27, 2024

Measles cases rose 20% worldwide in 2023, per new report

Measles vaccination coverage globally has still not recovered to pre-Covid levels, a fact that contributed to a 20% increase in measles cases in 2023 over

November 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.